Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Fiona Simpkins, M.D.

Fiona Simpkins, M.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER: Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecol Oncol 145(3):413-419, Jun 2017.

Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clin. Cancer Res 23(12):3097-3108, Jun 2017.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM: VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol Med 9(3):304-318, Mar 2017.

George E, Simpkins F, Ragland R, Rafail S, R Zhang, Morgan MA, Herlyn M, Brown E: Targeting the TR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models. Poster presented at: Society of Gynecologic Oncology, National Harbor, MD Mar 2017.

Rose PG, Ali S, Moslemi-Kebria M, Simpkins F: Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. Int J Gynecol Cancer 27(3):452-458, Mar 2017.

Chen J, Solomides C, Simpkins F, Simpkins H: The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol Page: doi: 10.1007/s00280-016-3225-1. [Epub ahead of print] Jan 2017.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760(doi: 10.1172/jci.insight.89760), Jan 2017.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N: RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 1;126(8):3145-57, Aug 2016.

Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Ko E, Schmitz K: Race-based disparities in loss of functional independence after hysterectomy for uterine cancer. Support Care Cancer 24(8):3573-80: Aug 2016.

George E, Kim H, Ragland R, Brown E, Butler L, Gilad O, Tanyi J, Zhang R, Krepler C, Lee R, Morgan M, Burger R, Ko E, Kim S, Herlyn M, Simpkins F : Capitalizing on synthetic lethality in homologous recombination deficient high grade serous ovarian cancers with a novel ATR inhibitor. Poster and published as abstract for the SGO meeting. San Diego, CA, April 2016.

back to top
Last updated: 08/02/2017
The Trustees of the University of Pennsylvania